BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 35873032)

  • 1. Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities.
    Ren X; Li Y; Nishimura C; Zang X
    Genes Dis; 2022 Sep; 9(5):1181-1193. PubMed ID: 35873032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.
    Pulanco MC; Madsen AT; Tanwar A; Corrigan DT; Zang X
    Cell Mol Immunol; 2023 Jul; 20(7):694-713. PubMed ID: 37069229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 5. B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression.
    Lu Y; Wu F; Cao Q; Sun Y; Huang M; Xiao J; Zhou B; Zhang L
    Oncogene; 2022 Jan; 41(5):704-717. PubMed ID: 34839353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer.
    Chen Y; Chen Z; Chen R; Fang C; Zhang C; Ji M; Yang X
    Future Oncol; 2022 May; 18(14):1757-1775. PubMed ID: 35232247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
    Hack SP; Zhu AX; Wang Y
    Front Immunol; 2020; 11():598877. PubMed ID: 33250900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
    Cheng H; Janakiram M; Borczuk A; Lin J; Qiu W; Liu H; Chinai JM; Halmos B; Perez-Soler R; Zang X
    Clin Cancer Res; 2017 Feb; 23(3):825-832. PubMed ID: 27553831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
    Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
    Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC.
    Li X; Lian Z; Wang S; Xing L; Yu J
    Cancer Lett; 2018 Apr; 418():1-9. PubMed ID: 29309815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways.
    Wang F; Cali Daylan AE; Deng L; Yang J; Sharma J; Su C; Li S; Zang X; Halmos B; Borczuk A; Cheng H
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma.
    Chen Y; Hu R; Li X; Shi Z; Tian H; Feng J; Yu S
    Pathol Res Pract; 2020 Oct; 216(10):153134. PubMed ID: 32853956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
    Cheng H; Borczuk A; Janakiram M; Ren X; Lin J; Assal A; Halmos B; Perez-Soler R; Zang X
    Clin Cancer Res; 2018 Apr; 24(8):1954-1964. PubMed ID: 29374053
    [No Abstract]   [Full Text] [Related]  

  • 16. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.
    To KKW; Fong W; Cho WCS
    Front Oncol; 2021; 11():635007. PubMed ID: 34113560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
    Saxena P; Singh PK; Malik PS; Singh N
    Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.